Tag: Drug Innovation ⋅ Page 1

Symposium – Protecting the Public While Fostering Innovation and Entrepreneurship: First Principles for Optimal Regulation

In a one-day symposium, hosted by the law school’s Center for Intellectual Property & Entrepreneurship and Business, Entrepreneurship, and Tax Law Review, a distinguished group of panelists will consider both substantive principles for regulating effectively in particular areas (e.g., financial markets, telecommunications, prescription drugs, network technologies) and broader procedural questions about how regulations should be crafted. What substantive principles should guide…

Professor Lietzan Featured on Webcast about New Uses for Established Drugs

On March 29, Professor Erika Lietzan was the featured speaker in a webcast from the Syracuse College of Law’s IP Tech Law Center.  She spoke with Shubha Ghosh about ensuring effective patent and regulatory exclusivity incentives for the development of new uses for already established drugs.  Her recent article on this topic, “Paper Promises for Drug Innovation” will be published…

Erika Lietzan Featured on ‘The Week in Health Law’ Podcast

Professor Lietzan was recently a guest on “This Week in Health Law,” a commuting-length podcast that tackles thorny issues in health law and policy. She discussed her research on the relationship between drug innovation and incentives for innovation, and the conversation touched on large molecule drugs, biosimilars, data exclusivity and market exclusivity, patent protection, and her extensive empirical research on…